IDH1 and central nervous system cancer: Treatment with IDH-C35, a selective mutant IDH-1 inhibitor, restored chemokine expression, promoted T-cell infiltration, and increased the efficacy of therapeutic peptide vaccination against IDH-mutated gliomas in mice [57].